10-K: MapLight Therapeutics Reports $161.2M Net Loss, Advances CNS Pipeline

MapLight Therapeutics reported a significant net loss in 2025 while progressing its lead CNS drug candidates, ML-007C-MA and ML-004, through Phase 2 clinical trials with key data expected in 2026 and 2027.

Summary

• MapLight Therapeutics, a clinical-stage biopharmaceutical company, focuses on central nervous system (CNS) disorders, leveraging a discovery platform to identify and target neural circuits linked to disease.
• The company's lead product candidate, ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist (ML-007) and a peripherally acting anticholinergic (PAC), is being developed for schizophrenia and Alzheimer's disease psychosis (ADP).
• ML-007C-MA has been evaluated in four Phase 1 trials with 270 healthy participants and over 1,500 doses, demonstrating potential as a well-tolerated treatment with convenient dosing.
• The ZEPHYR Phase 2 trial for schizophrenia is expected to reach target enrollment of 300 participants in April 2026 and report topline results in Q3 2026.
• The VISTA Phase 2 trial for ADP is expected to report topline results in 2H 2027; ML-007C-MA received Fast Track designation from the FDA for hallucinations and delusions associated with ADP in December 2025.
• The second product candidate, ML-004, a 5-HT1B/1D agonist, is in a Phase 2 trial (IRIS) for social communication deficit and/or irritability in autism spectrum disorder (ASD), with topline results expected in Q3 2026.
• Preclinical programs include ML-009 (GPR52 PAM for hyperactivity/impulsivity, IND-enabling studies in 2027), ML-055 (next-generation M1/M4 muscarinic agonist, preclinical candidate nomination in 2026), and ML-021 (M4 antagonist for Parkinson's motor deficits, IND-enabling studies in 2027).
• The company reported a net loss of $161.2 million for the year ended December 31, 2025, an increase from $77.6 million in 2024, with an accumulated deficit of $360.5 million.
• Cash, cash equivalents, and investments totaled $453.1 million as of December 31, 2025, projected to fund operations through 2027.
• MapLight Therapeutics completed an initial public offering (IPO) in October 2025, raising $261.6 million in net proceeds, and a concurrent private placement yielding $7.5 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative filing due to significant and increasing net losses, highlighting the substantial capital required for a clinical-stage biopharmaceutical company. While there is positive progress in clinical trials and a Fast Track designation, the financial burn rate and inherent risks of drug development warrant caution.

Positives

• ML-007C-MA received FDA Fast Track designation in December 2025 for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP), potentially expediting development and review.
• The lead candidate, ML-007C-MA, demonstrated a generally well-tolerated safety and tolerability profile in Phase 1 trials, with most adverse events being mild, transient, and self-limiting.
• ML-007C-MA's formulation allows for convenient onceor twice-daily dosing and does not require administration in a fasted state, potentially improving patient adherence.
• Preclinical data for ML-007C-MA suggest strong activation of both M1 and M4 receptors, with potential to improve positive, negative, and cognitive symptoms in schizophrenia and Alzheimer's disease.
• ML-007 demonstrated pro-cognitive effects in animal models of Alzheimer's disease, improving spatial and social memory.
• The company successfully completed its IPO in October 2025, raising $261.6 million in net proceeds, significantly bolstering its cash position.
• ML-004, for Autism Spectrum Disorder (ASD), has completed enrollment in its Phase 2 IRIS trial, with topline results expected in Q3 2026.
• The company is advancing multiple preclinical programs (ML-009, ML-055, ML-021), indicating a robust and diversified pipeline beyond its lead candidates.
• The company's intellectual property portfolio includes 86 issued patents and pending applications, with composition of matter patents for ML-007 expected to expire between 2031 and 2032, and combination patents potentially extending to 2042-2046.

Negatives

• The company incurred substantial net losses of $161.2 million in 2025, a significant increase from $77.6 million in 2024, and has an accumulated deficit of $360.5 million.
• MapLight Therapeutics is a clinical-stage company with a limited operating history and no history of commercializing products, making future viability uncertain.
• The company has not generated any revenue from product sales to date and does not expect to do so for at least the next several years.
• Substantial additional capital will be required to complete clinical development and commercialization of product candidates, and there is no assurance that such funding will be available on acceptable terms or at all.
• Raising additional capital through equity or convertible debt could dilute existing stockholders' ownership interests.
• Clinical development is a lengthy, expensive, and unpredictable process, with a high risk of failure at any stage.
• The company relies heavily on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs), which introduces risks related to supply, quality, regulatory compliance, and potential disruptions.
• Past clinical holds on ML-004 (partial hold lifted in October 2024) and ML-007C-MA (lifted in July 2024) highlight regulatory and development risks.
• The market for CNS disorders is highly competitive, with many pharmaceutical and biotechnology companies developing competing therapies, some with significantly greater resources.

Risks

• The company has a limited operating history and no history of commercializing products, making it difficult to evaluate its future viability.
• Substantial additional capital is required to achieve goals, and failure to obtain it could delay, limit, reduce, or terminate product development or commercialization efforts.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Clinical development is lengthy, expensive, and characterized by uncertain outcomes; earlier study results may not predict future trial results.
• Delays or difficulties in patient enrollment and dosing in clinical trials may delay or prevent regulatory approvals.
• Significant adverse events or undesirable side effects from product candidates may delay/prevent regulatory approval, limit market acceptance, or result in negative consequences post-approval.
• The company faces intense competition from pharmaceutical and biotechnology companies, academic institutions, and governmental agencies.
• Benefits from current or future collaborations or licensing arrangements may not be realized, and future partnerships may be unsuccessful.
• Regulatory approval for product candidates in the U.S. or other jurisdictions is uncertain, and any approval may be for a narrower indication than sought.
• High dependence on key executive officers; inability to retain or recruit management/scientific personnel could harm the business.
• Expected expansion of capabilities (clinical development, manufacturing, regulatory, sales/marketing) may lead to difficulties in managing growth and disrupt operations.
• Manufacturing of product candidates is complex, and third-party manufacturers may encounter production difficulties, delaying or halting supply for trials or commercialization.
• Inability to obtain and maintain sufficient intellectual property protection or if the scope is not broad enough, competitors could develop similar products.
• Reliance on third parties for supply and manufacturing subjects the company to risks of insufficient quantities, unacceptable quality, or regulatory non-compliance.
• An active and liquid trading market for common stock may not be sustained, leading to volatility and potential losses for investors.
• Interim, 'topline,' and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Changes in methods of product candidate manufacturing or formulation may result in additional costs or delays.
• Failure to discover, develop, and commercialize other product candidates could impair business growth and strategic objectives.
• Concentration of research and development efforts on CNS disorders, a field with historical challenges in drug development (e.g., subjective patient-reported outcomes, placebo effect).
• Potential for product liability lawsuits, which could incur substantial liabilities and limit commercialization.
• Ongoing regulatory obligations and review post-approval, with potential for significant additional expense and penalties for non-compliance.
• Uncertainty related to pricing, coverage, and reimbursement for product candidates, which could limit commercial success.
• Disruptions at the FDA and other government agencies (e.g., funding shortages, staffing limitations, global health concerns) could hinder timely development, approval, or commercialization.
• Uncertainty regarding the Section 505(b)(2) regulatory approval pathway, which could lead to longer timelines, higher costs, and greater risks.
• Current and future healthcare reform legislation or regulation may increase costs and adversely affect pricing.
• Stringent and evolving U.S. and foreign laws, regulations, and contractual obligations related to data privacy and security, with potential for investigations, litigation, fines, and business disruptions.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws, which could impair international market competition.
• Fast Track designation does not guarantee faster development, review, or approval, nor does it increase the likelihood of regulatory approval.
• Employees, independent contractors, consultants, and collaborators may be improperly classified or engage in misconduct, including non-compliance with regulatory standards.
• Compromise of information technology systems or data could lead to adverse consequences, including regulatory actions, litigation, and reputational harm.
• Business disruptions (e.g., natural disasters, disease outbreaks) could seriously harm future revenue and financial condition.
• Challenges in protecting intellectual property rights globally, including the high cost of filing/defending patents and varying legal protections in different countries.
• Changes in patent law (e.g., America Invents Act, U.S. Supreme Court rulings) could diminish the value of patents.
• Patent terms may be inadequate to protect competitive position for a sufficient time.
• Inadequate protection of trademarks and trade names could hinder name recognition and adversely affect business.
• Potential for claims challenging inventorship or ownership of patents and other intellectual property.
• Reliance on in-licensed intellectual property, with risks if obligations are not met or disputes arise.
• Executive officers, directors, and principal stockholders have significant influence over matters submitted to stockholders for approval.
• Anti-takeover provisions in corporate charter documents and Delaware law could make an acquisition more difficult.
• Increased costs and demands on management as a newly public company, including compliance with SEC and Nasdaq regulations.
• Inability to design and maintain effective internal control over financial reporting could lead to loss of investor confidence.
• Limitations on the ability to use net operating loss carryforwards and certain other tax attributes due to ownership changes.
• Changes in tax laws or regulations may have a material adverse effect on cash flow and financial condition.
• Unfavorable global economic conditions (e.g., inflation, interest rates, geopolitical conflicts) could adversely affect business.

Future Outlook

The company expects to continue incurring significant and increasing expenses and net losses as it advances its current and future product candidates through preclinical and clinical development and seeks regulatory approvals. Topline results for the ZEPHYR Phase 2 trial in schizophrenia and the IRIS Phase 2 trial in ASD are anticipated in Q3 2026, while topline results for the VISTA Phase 2 trial in ADP are expected in 2H 2027. The company plans to nominate a preclinical candidate for ML-055 in 2026 and complete IND-enabling studies for ML-009 and ML-021 in 2027. Substantial additional funding will be required beyond existing cash to complete development of any product candidate.

Management Comments

• Management believes their deep understanding of causal links between neural circuit modulation and disease-specific behaviors will enable the development of therapeutics with efficacy, safety, tolerability, and ease-of-use advantages.
• Management believes ML-007C-MA has demonstrated the potential to be a well-tolerated treatment option with convenient dosing, achieving or exceeding CSF exposures expected to result in improvement across key symptom domains.
• Management believes that strong activation of both M1 and M4 receptors by ML-007C-MA has the potential to improve both positive and negative symptoms of schizophrenia and cognitive symptoms.
• Management intends to explore potential strategies for further development of ML-004 based on the results from the IRIS trial.
• Management believes the benefits of anti-takeover provisions, including increased protection of the company's potential ability to negotiate with proponents of unfriendly proposals, outweigh the disadvantages of discouraging takeover proposals.

Industry Context

StockSavvy.ai notes that MapLight Therapeutics operates in the challenging but high-need CNS disorder market, where there is a significant unmet need for effective treatments for schizophrenia, Alzheimer's disease psychosis (ADP), and autism spectrum disorder (ASD). The company's focus on muscarinic receptors for schizophrenia and ADP aligns with a novel mechanism of action, as evidenced by the recent FDA approval of Cobenfy (KarXT) by Bristol Myers Squibb, the first such approval in decades. MapLight aims to differentiate ML-007C-MA from competitors like Cobenfy by optimizing the pharmacokinetic synchronization of agonist and antagonist components to mitigate side effects and improve dosing convenience. For ASD, the company is targeting social communication deficits, a core symptom for which no FDA-approved therapies exist, contrasting with the atypical antipsychotics (e.g., ABILIFY, RISPERDAL) currently approved only for irritability. The industry faces challenges with subjective patient-reported outcomes and placebo effects in neuropsychiatric trials, which MapLight acknowledges and attempts to mitigate through study design.

Comparison to Industry Standards

• ML-007C-MA aims to improve upon existing muscarinic agonists like Cobenfy (KarXT, Bristol Myers Squibb) by synchronizing agonist/antagonist pharmacokinetics to mitigate proand anticholinergic side effects, potentially offering enhanced tolerability and more convenient dosing (onceor twice-daily without fasting vs. Cobenfy's twice-daily with 3-8 day titration and fasting requirements for schizophrenia, or three times a day with 5-week titration for ADP).
• Unlike M4-only selective agonists (which have shown mixed or negative efficacy in large trials and are not expected to address cognitive symptoms), ML-007C-MA targets both M1 and M4 receptors, which is believed to be important for broader efficacy across positive, negative, and cognitive symptoms in schizophrenia and Alzheimer's disease.
• For ASD, ML-004 is being developed for core social communication deficits, an area with no FDA-approved pharmaceutical treatments. This contrasts with current standard-of-care atypical antipsychotics like ABILIFY (Otsuka Pharmaceutical Co., Ltd.) and RISPERDAL (Johnson & Johnson), which are approved only for irritability symptoms and are associated with serious side effects (e.g., weight gain, EPS, metabolic abnormalities).
• Preclinical studies for ML-007 demonstrated approximately 10-fold greater potency by dose compared to xanomeline (the agonist in Cobenfy) in multiple in vivo models, suggesting a potentially more effective therapeutic profile.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently party to any material legal proceedings, nor is it aware of any such proceedings contemplated by a government authority.

Related Party Transactions

• The company entered into an Assignment and Assumption Agreement with Stellaromics, Inc. in October 2023, receiving an equity investment in Stellaromics common stock. As of December 31, 2025, the company held approximately 3.7% of all outstanding stock of Stellaromics.
• Christopher A. Kroeger, M.D. (CEO and Director of MapLight) is a member of Stellaromics' board of directors and an equity holder of Stellaromics.
• Catalyst4, Inc., MapLight's largest stockholder, holds a controlling interest in Stellaromics as of December 31, 2025.
• An advisor agreement with Robert Malenka, M.D., Ph.D. (a Director of MapLight) resulted in $0.1 million in research and development expense in both 2025 and 2024 for his service on the scientific advisory board. Effective January 1, 2026, he will no longer receive monetary compensation but will be reimbursed for expenses.
• The spouse of an executive officer was employed by the company from November 2023 to April 2025, with compensation (annual salary and RSU grants) being de minimis in 2025 and approximately $0.3 million in 2024.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future capital raises and potential volatility in stock price due to clinical trial outcomes and market conditions. The anti-takeover provisions could limit their ability to influence corporate control.
• **Employees:** Benefit from equity incentive plans (2019 and 2025 Plans) and an Employee Stock Purchase Plan (2025 ESPP). The company's growth plans suggest potential for increased headcount and career opportunities, but also risks associated with managing rapid expansion.
• **Customers (future patients):** Stand to benefit from the development of novel therapies for debilitating CNS disorders like schizophrenia, ADP, and ASD, addressing significant unmet medical needs and potentially offering improved efficacy, safety, and ease of use compared to current treatments.
• **Suppliers/CMOs/CROs:** The company's reliance on third-party manufacturers and clinical research organizations means continued business for these partners, but also subjects them to strict regulatory compliance and quality requirements.
• **Creditors:** The company's substantial net losses and need for future funding indicate a higher risk profile, though the recent IPO has significantly improved its cash position in the short term.

Next Steps

• Reach target enrollment of 300 participants in the ZEPHYR Phase 2 trial for schizophrenia in April 2026.
• Report topline results for the ZEPHYR Phase 2 trial in schizophrenia in Q3 2026.
• Report topline results for the IRIS Phase 2 trial for ASD in Q3 2026.
• Nominate a preclinical candidate for ML-055 to advance to IND-enabling studies in 2026.
• Report topline results for the VISTA Phase 2 trial for ADP in 2H 2027.
• Complete IND-enabling studies for ML-009 (GPR52 PAM program) in 2027.
• Complete IND-enabling studies for ML-021 (M4 antagonist program) in 2027.
• Explore potential strategies for further development of ML-004 based on IRIS trial results.
• Continue to raise substantial additional capital to fund ongoing operations and development.

Key Dates

Recommendation

MapLight Therapeutics is a clinical-stage biopharmaceutical company with a promising pipeline targeting significant unmet needs in CNS disorders, including Fast Track designation for ML-007C-MA. The recent IPO has provided substantial capital, funding operations through 2027. However, the company is incurring significant and increasing net losses, has no product revenue, and faces inherent high risks associated with clinical development, regulatory approvals, and the need for substantial future funding. Key clinical trial results are anticipated in 2026 and 2027, which will be critical catalysts. Given the early stage of development and the balance of potential upside with considerable financial and operational risks, a 'hold' recommendation is appropriate for investors who are comfortable with high-risk, high-reward biotech investments and are awaiting further clinical data.

Keywords

Biopharmaceutical, CNS disorders, Schizophrenia, Alzheimer's disease psychosis, Autism spectrum disorder, ML-007C-MA, ML-004, Muscarinic agonist, 5-HT1B/1D agonist, Clinical-stage, Phase 2 trials, Fast Track designation, Drug development, Neuroscience, Intellectual property, SEC filing, 10-K, Biotech, Pharmaceutical